Profound Medical Corp. (PROF)
$10.09
+0.09 (+0.90%)
Rating:
Recommendation:
-
| Symbol | PROF |
|---|---|
| Price | $10.09 |
| Beta | 1.214 |
| Volume Avg. | 0.02M |
| Market Cap | 214.519M |
| Shares () | - |
| 52 Week Range | 5.26-15.49 |
| 1y Target Est | - |
| DCF Unlevered | PROF DCF -> | |
|---|---|---|
| DCF Levered | PROF LDCF -> | |
| ROE | -63.57% | Strong Sell |
| ROA | -57.86% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 21.07% | Neutral |
| P/E | -7.26 | Strong Sell |
| P/B | 5.60 | Strong Buy |
Latest PROF news
About
Download (Excel)Dr. Arun Swarup Menawat MBA, Ph.D.
Healthcare
Medical Devices
NASDAQ Capital Market
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.